HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody. The phase 1 clinical trial in China is a multicenter, open-label study, which will assess HMPL-A83’s safety, tolerability, pharmacokinetics, and preliminary efficacy in […]
Menarini acquisition of Stemline : Menarini Group, an Italian pharma and diagnostics company, has agreed to acquire US biopharma company Stemline Therapeutics in a deal worth up to $677 million. Stemline Therapeutics is engaged in the development and commercialization of novel oncology therapeutics. Its acquisition enables Menarini Group to establish its footprint in the US […]
What are the Characteristics of Neoplasia? Neoplasia comprises of both malignant and benign tumors. What are the differences between Malignant Tumors and Benign Tumors? Benign neoplasm: If there are clusters of tumor cells in a single mass, they are called benign tumors. These tumors are not malignant. Benign tambours are not harmful in general, but […]